Blocking caspase-9, an enzyme involved in cell death, may be a potential treatment target for pulmonary fibrosis, a ...

Columnist Sam Kirton explains when the new FDA-approved IPF treatment Jascayd might be made available to patients.

Guest writer Kylene Henderson recalls the lengthy journey she and her husband faced to get answers and a pulmonary fibrosis diagnosis.

Software that uses artificial intelligence to analyze medical imaging tests may help facilitate earlier diagnosis and more accurate monitoring of pulmonary fibrosis in people with underlying lung ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Living with a chronic and progressive disease like pulmonary fibrosis (PF) can be challenging, and there are many issues a person with PF needs to consider, including lifestyle changes, coping with ...

Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...